No Detail Found!

Assessing tecoma stans compounds as GLP-1 agonists and inhibitors of alpha-glucosidase/alpha-amylase

Author(s)
HATICE AKKAYA Department Biochemistry, Faculty of Pharmacy, University of Health Sciences,Istanbul,Turkey
Abstract
The identification of bioactive metabolites in Tecoma stans reveals its biological benefits and traditional uses, particularly in the context of diabetes mellitus. To identify key compounds and assess toxicity risks, ADME-Tox and drug similarity tests were conducted. Ligands identified from the ADME assay were analyzed through In silico molecular docking studies against the GLP-1 receptor, which plays a crucial role in insulin sensitivity, blood sugar regulation, and energy metabolism control. Among the 26 secondary metabolites identified through ADME, the luteolin flavonoid emerged as the most active ligand with a docking score of -6 kcal/mol and a binding energy of -74.76 kcal/mol. Active compounds such as luteolin found in Tecoma stans have been shown to have the potential to treat hyperglycemia through the inhibition of a-glucosidase and a-amylase. The results suggest that the progressive complications of diabetes can be effectively managed.
Publication Details
Page(s) 1341-1347
Published Journal: Pakistan Journal of Botany, Volume: 57, Issue: 4, Year: 2025

Request the full text from PASTIC

Keywords
a-glucosidase, Diabetes Mellitus, Diabetes Mellitus, hyperglycemia, in silico, a-amylase, a-amylase, Tecoma stans
References
Abdelli I.,Benariba N.,Adjdir S.,Fekhikher Z.,Terki M.,Benramdane H.,Ghalem S. .2021 .In silico evaluation of phenolic compounds as inhibitors of Α- amylase and Α-glucosidase. J. Biomol. Struct. Dynam., 39(3) : 816-822.
Adasme M.F.,Linnemann K.L.,Bolz S.N.,Kaiser F.,Salentin S.,Haupt V.J.,Schroeder M. .2021 .PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA. Nucl. Acids Res, 49(W1) : W530-W534.
Akkaya H.,Özmaldar A. .2024 .In silico trıal approaches between phytochemıcal composıtıon of verbena offıcınalıs and lıver cancer targets. J. Facul. Pharm, 48(3) : 975-992.
Akkaya E.,Sümer E. .2024 .In silico approaches on phenylalanıne hydroxylase ınhıbıtor-related compounds used ın parkınson's dısease treatment. J. Facul. Pharm, 48(2) : 513-524.
Alonso-Castro A.J.,Zapata-Bustos R.,Romo-Yañez J.,Camarillo-Ledesma P.,Gómez-Sánchez M.,SalazarOlivo L.A. .2010 .The antidiabetic plants Tecoma stans (L.) Juss. ex Kunth (Bignoniaceae) and Teucrium cubense Jacq (Lamiaceae) induce the incorporation of glucose in insulinsensitive and insulin-resistant murine and human adipocytes. J. Ethnopharm., 127(1) : 1-6.
Anand M.,Basavaraju R.,Ethnopharm Kunth. J. .2021 .A review on phytochemistry and pharmacological uses of Tecoma stans (L.) Juss. ex. , 265 : 113270.
Anandan S.,Gowtham H.G.,Shivakumara C.S.,Thampy A.,Singh S.B.,Murali M.,Shivamallu C.,Pradeep S.,Shilpa N.,Shati A.A.,Alfaifi M.Y.,Elbehairi S.E.I.,Ortega-Castro J.,Frau J.,Flores-Holguín N.,Kollur S.P.,Glossman-Mitnik D. .2022 .Integrated approach for studying bioactive compounds from Cladosporium spp. against estrogen receptor alpha as breast cancer drug target. Sci. Rep, 12(1) : 22446.
Andrade E.L.,Bento A.F.,Cavalli J.,Oliveira S.K.,Schwanke R.C.,Siqueira J.M.,Freitas C.S.,Marcon R.,Calixto J.B. .2016 .Non-clinical studies in the process of new drug development- Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies. Brazil. J. Med. & Biolog. Res. Revista Brasil. de Pesquisas Med, 49(12) : e5646.
Asgar A. .2013 .Anti-Diabetic Potential of Phenolic Compounds: A Review, Intern. , 16 : 91-103.
Aziz N.,Kim M.Y.,Cho J.Y. .2018 .Anti-inflammatory effects of luteolin: A review of In vitro, In vivo, and In silico studies. J, 225 : 342-358.
Bakr R.O.,Fayed M.A.A.,Salem M.A.,Hussein A.S. .2019 .Tecoma stans: Alkaloid profile and antimicrobial activity. J. Pharm. Bioallied Sci., 11(4) : 341-347.
Bischoff H. .1995 .The mechanism of alpha-glucosidase inhibition in the management of diabetes. Clin. Invest. Med, 18(4) : 303-311.
Bissantz C.,Kuhn B.,Stahl M. .2010 .A medicinal chemist's guide to molecular interactions. J. Med, 53(14) : 5061-5084.
Butt S.S.,Badshah Y.,Shabbir M.,Rafiq M. .2020 .Molecular docking using chimera and autodock vina software for Nonbioinformaticians MIR Bioinform. , 1(1) : e14232.
Cao D.,Zhu G.Y.,Lu Y.,Yang A.,Chen D.,Huang H.J.,Peng S.X.,Chen L.W.,Li Y.W. .2020 .Luteolin suppresses epithelial-mesenchymal transition and migration of triplenegative breast cancer cells by inhibiting YAP/TAZ activity. Biomed. Pharm., 129 : 110462.
Chen X.,Li H.,Tian L.,Li Q.,Luo J.,Zhang Y. .2020 .Analysis of the physicochemical properties of acaricides based on Lipinski's rule of five. J. Comp. Biol., 27(9) : 1397-1406.
Çetinkaya M.,Baran Y. .2023 .Therapeutic Potential of Luteolin on Cancer. Vaccines, 11(3) : 554.
Daina A.,Michielin O.,Zoete V. .2017 .SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep., 7 : 42717.
Del Águila Conde M.,Febbraio F. .2022 .Risk assessment of honey bee stressors based on In silico analysis of molecular interactions. J. Europ. Food Saf, 20(Suppl 2) : e200912.
Djeujo F.M.,Ragazzi E.,Urettini M.,Sauro B.,Tonelli M.,Froldi G. .2022 .Magnolol and luteolin ınhibition of α-glucosidase activity: Kinetics and type of ınteraction detected by In vitro and In silico studies. Pharmac, 15 : 205.
Djeujo F.M.,Stablum V.,Pangrazzi E.,Ragazzi E.,Froldi G. .2023 .Luteolin and vernodalol as bioactive compounds of leaf and root vernonia amygdalina extracts: Effects on α- glucosidase, glycation, ros, cell viability, and In silico ADMET parameters. , 15(5) : 1541.
Feng T.,Zheng Z.,Hou C.,Lv A.,Xue B.,Han B.,Sun X.,Wei Y. .2020 .Luteolin, an aryl hydrocarbon receptor ligand, suppresses tumor metastasis In vitro. Oncol. Rep, 44(5) : 2231-2240.
Gupta A.,Jelinek H.F.,Al-Aubaidy H. .2017 .Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus. Diab. Metab, 11(3) : 225-230.
Hennessy M.,Spiers J.P. .2007 .A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharm. Res., 55(1) : 1-15.
Jaén M.L.,Vilà L.,Elias I.,Jimenez V.,Rodó J.,Maggioni L.,Ruiz-de Gopegui R.,Garcia M.,Muñoz S.,Callejas D.,Ferré T.,I. Grifoll T.,Andaluz A.,Ruberte J.,Haurigot V.,Bosch F. .2017 .Long-term efficacy and safety of ınsulin and glucokinase gene therapy for diabetes: 8-year follow-up in dogs. molecular therapy. Methods Clin. Develop., 6 : 1-7.
Kalay H.,Akkaya H. .2023 .Molecular Modelling of Some Ligands Against Acetylcholinesterase to Treat Alzheimer's Disease. J. Res. Pharm., 27(6) : 2199-2209.
Ç.F Kelleci,Karaduman G.,Chem G. .2023 .Machine Learning-Based Prediction of Drug-Induced Hepatotoxicity: An OvA-QSTR Approach. , 63(15) : 4602-4614.
Kieffer T.J.,Habener J.F. .1999 .The glucagon-like peptides. Endocrine Rev., 20(6) : 876-913.
Kim J.S.,Kwon C.S.,Son K.H. .2006 .Inhibition of alphaglucosidase and amylase by luteolin, a flavonoid. Biosci, 64(11) : 2458-2461.
Kuang Z.K.,Yang Z.X.,Guo Y.X.,Huan Y.O.,Su Z.D. .2021 .In silico prediction of GLP-1R agonists using machine learning approach. Chem, 75 : 3587-3598.
Latif W.,K.J. Lambrinos P.,Patel R.,Rodriguez R. .2023 .Stat Pearls. , : .
Mansoor A.,Mahabadi N.,Island (FL): StatPearls Publishing. N. .2023 .. , : .
Moezzi M.S. .2023 .Comprehensive In silico screening of flavonoids against SARS-CoV-2 main protease. J. Biomol Struct Dyn., 41(19) : 9448-9461.
Montanari F.,Ecker G.F. .2015 .Prediction of drug-ABCtransporter interaction-Recent advances and future challenges. Adv. Drug Deliv. Rev., 86 : 17-26.
Moral R.,Escrich E. .2022 .Influence of olive oil and its components on breast cancer: Molecular Mechanisms. , 27(2) : 477.
Nguyen T.H.,To H.L.,Nguyen T.B.,Nguyen N.K.,Pham H.T.,Nguyen C.H.,Nguyen H.H.,Nguyen N.H.,Nguyen T.H.,Duong T.H. .2023 .Tecomastane, a new megastigmane from the flowers of Tecoma stans. Nat. Prod. Res., 37(21) : 3563-3571.
Park S.H.,Kim J.H.,Lee D.H.,Kang J.W.,Song H.H.,Oh S.R.,Yoon D.Y. .2013 .Luteolin 8-C-β-fucopyranoside inhibits invasion and suppresses TPA-induced MMP-9 and IL-8 via ERK/AP-1 and ERK/NF-κB signaling in MCF-7 breast cancer cells. Biochimie, 95(11) : 2082-2090.
Poczta A.,Krzeczyński P.,Tobiasz J.,Rogalska A.,Gajek A.,Marczak A. .2022 .Synthesis and In vitro activity of novel melphalan analogs in hematological malignancy Cells. Int. J. Mol. Sci, 23(3) : 1760.
Puranik N.V.,Srivastava P.,Bhatt G.,Mary D.J.S. John,Limaye A.M.,Sivaraman J. .2019 .Determination and analysis of agonist and antagonist potential of naturally occurring flavonoids for estrogen receptor (ERα) by various parameters and molecular modelling approach. Sci. Rep, 9(1) : 7450.
Riyaphan J.,Pham D.C.,Leong M.K.,Weng C.F. .1877 .In silico Approaches to identify polyphenol compounds as α- glucosidase and α-amylase ınhibitors against type-ıı diabetes. Biomolecules, 11(12) : .
Schenone M.,Dančík V.,Wagner B.K.,Clemons P.A. .2013 .Target identification and mechanism of action in chemical biology and drug discovery. Nat. Chem, 9(4) : 232-240.
Setlur A.S.,Chandrashekar K.,Panhalkar V.,Sharma S.,Sarkar M.,Niranjan V. .2023 .In-silico-based toxicity investigation of natural repellent molecules against the human proteome: A safety profile design. Protocols, 06 : 23.
Shahzadi A.,Tariq N.,Sonmez H.,Waquar S.,Zahid A.,Javed M.A.,Ashraf M.Y.,Malik A.,Ozturk M. .2023 .Potential effect of luteolin, epiafzelechin, and albigenin on rats under cadmium-induced inflammatory insult: In silico and In vivo approach. , 11 : 1036478.
Sharma P.,Chandra S.S.,Tamta S. .2020 .In silico screening of potential antidiabetic phytochemicals from Phyllanthus emblica against therapeutic targets of type 2 diabetes. , 248 : 112268.
Şahin S. and N.,Dege S. and N. .2022 .Synthesis, characterization, computational analyses, In silico ADMET studies, and inhibitory action against SARS-CoV-2 main protease (Mpro) of a Schiff base. Turk. J. Chem, 46(5) : 1548-1564.
Telagari M.,Hullatti K. .2015 .In vitro α-amylase and α- glucosidase inhibitory activity of Adiantum caudatum Linn. and Celosia argentea Linn. extracts and fractions. Ind. J. Pharm., 47(4) : 425-429.
Upadhyay R.K. .2016 .Antidiabetic potential of plant natural products: A review. Int. J. Green Pharm, 10(3) : S96-S113.
Uysal S.,Ugurlu A.,Baloglu M.C.,Altunoglu Y.C.,Mollica A.,Custodio L.,Neng N.R.,Nogueira J.M.F.,Mahomoodally M.F. .2018 .Novel In vitro and In silico insights of the multi-biological activities and chemical composition of Bidens tripartita L. Food Chem. , 111 : 525-536.
van Ommen B.,H.M. van Keulen W.,Otten M.,Kasteleyn J.J.W.,Molema J.J.W.,I.M. de Hoogh N.H.,Chavannes M.E.,Numans A.W.M.,Evers H.,Pijl H. .2018 .From diabetes care to diabetes cure-the integration of systems biology, health, and behavioral change. Front. Endocrin., 8 : 381.
Vani S.,Venkateshappa R.,Nishitha H.,Shashidhar A.B.,Hegde M.,Alagumuthu M. .2024 .In silico analysis of natural inhibitors against HPV E6 protein. Curr. Comp. Aided Drug Design., 20(3) : 303-311.
Weber A.E. .2004 .Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J. Med, 47(17) : 4135-4141.
Medicine Anonymous. 2009. Traditional .2023 .. (Accessed, 11 : 22.
Zhang C.,Wu C. .2022 .In vivo evaluation of the developmental toxicity, estrogenic activity, and mutagenicity of four natural phenolic flavonoids at low exposure levels. ACS Omega, 7(6) : 4757-4768.
0

Citations

0

Downloads

119

Views